

Speaker Biographies

Jeff Miller

Vice President, General Manager, CC5 Program, Alnylam

Mr. Miller joined Alnylam in May 2016 with 20 years of experience in the biotechnology and pharmaceutical industry. Prior to joining Alnylam, he held a variety of general management and commercial leadership roles in the United States, Europe, and Canada. While with Alexion, Merck Serono, Boehringer Ingelheim, and Eli Lilly, he worked across many disease areas in Primary Care, Specialty Care, Oncology, and Rare Diseases. Jeff earned his Bachelor of Arts in Communications from the State University of New York at Oswego and his MBA from Boston University.

Anita Hill, MBChB (Hons), MRCP, FRCPath, Ph.D.

Consultant Haematologist for Leeds Teaching Hospitals NHS Trust, UK, and Honorary Senior Lecturer at the University of Leeds

Anita Hill is a Consultant Haematologist for Leeds Teaching Hospitals NHS Trust, UK and also Honorary Senior Lecturer at the University of Leeds. She works within the nationally commissioned National PNH Service based in Leeds. Prior to this, Dr. Hill worked as a Consultant Haematologist for Bradford Teaching Hospitals NHS Foundation Trust, where she was the Lead for Clinical Trials and Research. Dr. Hill received her medical degree with distinctions and honours from the University of Sheffield, UK. She did her post-graduate training in Sheffield Teaching Hospitals NHS Trust, St George's Hospital, London and the Royal Marsden Hospital, London. Dr. Hill went on to specialize in hematology at Leeds Teaching Hospitals NHS Trust. She was awarded her PhD for exploring the role of complement and nitric oxide in the pathophysiology of PNH and other hemolytic anemias. Dr. Hill has been co-investigator for trials in PNH and lymphoma, and has published papers in both these areas. She is a member of the Data Sub-Committee for the PNH Global Registry, as well as a member of the Royal College of Pathologists, British Society of Haematology, International PNH Interest Group and Committee member for the BBTS Red Cell Specialist Interest Group. She has served a 3 year term as an elected member of the North of England Regional Council, Royal College of Pathologists.

Pushkal Garg, M.D.

SVP, Clinical Development, Alnylam

Dr. Garg joined Alnylam in 2014 with close to 15 years of experience in clinical drug development. Prior to joining Alnylam, he served as Vice President, Global Clinical Research, Immunoscience at Bristol-Myers Squibb (BMS). In this role he was responsible for strategic leadership of the Immunoscience franchise and the successful development of multiple clinical assets across immune-mediated diseases in the areas of rheumatology, gastroenterology, nephrology, and transplantation. During his eight-year tenure at BMS, he was instrumental to the late-stage development and approval of Nulojix® (belatacept) for kidney transplant recipients, and for supplementary biologics license applications (BLA) for Orencia® (abatacept) around the world. Previously, Pushkal was at Millennium Pharmaceuticals, where he worked in various roles of increasing responsibility, overseeing the clinical development of multiple small molecule and biologic therapeutics for the treatment of inflammatory disorders. Pushkal received a Bachelor of Arts with high honors in Biochemistry from the University of California, Berkeley, and an M.D. from the University of California, San Francisco. He completed residency training in Internal Medicine at UCSF, was a fellow in the Robert Wood Johnson Clinical Scholars Program at Johns Hopkins University, and served on the faculty of Harvard Medical School and the Brigham & Women's Hospital in Boston prior to joining industry.